Varenicline: A novel nicotinic receptor partial agonist for smoking cessation

Journal of Pharmacy Technology

Volumn 23, Issue 1, 2007, Pages 23-29

  Kerr, Jessica L ^a   Timpe, Erin M ^a   Karpinski, Julie P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC AGENT; NICOTINIC RECEPTOR; ORGANIC CATION TRANSPORTER 2; PARTIAL AGONIST; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INSOMNIA; MEDICAL LITERATURE; MEDLINE; NAUSEA; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING CESSATION; TOBACCO; TOBACCO DEPENDENCE; TREATMENT DURATION; VOMITING;

EID: 33847126257     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250702300105     Document Type: Review

References (20)

1. Cigarette smoking among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 2005;54:1121-4.
2. Tobacco or health: a global status report. Geneva: World Health Organization, 1997.
3. Healthy people 2010: understanding and improving health. 2nd ed. Washington, DC: US Department of Health and Human Services, 2000. www.healthypeople.gov (accessed 2006 Jun 2).
4. Coe JW, Vetelino MG, Bashore CG, et al. In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 2005;15:2974-9.
5. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-7.
6. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 2000;283:3244-54.
7. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;3:CD000146.
8. Package insert. Chantix (varenicline). New York: Pfizer, May 2006.
9. Fagerstrom K, Balfour DJ. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 2006;15:107-16.
10. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006;60:571-6.
11. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7.
12. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006;34:121-30.
13. Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 2006;46:1234-40.
14. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7.
15. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
16. Reeves K, Watsky E, Williams K, Azoulay S, Billing B, Gong J. The safety of varenicline taken for 52 weeks for smoking cessation (poster). Presented at: 12th Annual Meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL, February 15-18, 2006.
17. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch Intern Med 2006;166:1561-8.
18. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
19. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
20. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300.